Moldovan, D <br/><br/>
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.  [electronic resource] 

 -  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology  Jun 2012 
 - 929-35 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2222 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2222.2012.03984.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Angioedemas, Hereditary--drug therapy<br/>Complement C1 Inhibitor Protein--administration & dosage<br/>Complement Inactivating Agents--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Recombinant Proteins--therapeutic use<br/>Risk Factors<br/>Treatment Outcome<br/>Young Adult